Characteristics of included studies
Study design | Number joints (hip/knees) | Gender (male:female) | Country origin | Mean age (years) | Follow-up duration (months) | Pain outcome measures | Functional outcome measures | |
Ahedi et al54 | Observational cohort | 198 hips | 111:87 | Australia | UTD | 132 | WOMAC Pain | NA |
Akelman et al20 | RCT | 107 knee | UTD | USA | 23.5 | 84 | KOOS pain; SF-36 Body pain | SF-36 Physical; AP laxity; IKDC2000 |
Amin et al55 | Observational cohort | 265 knees | 152:113 | USA | 67 | 30 | VAS Pain | WOMAC Function |
Antony et al56 | Observational cohort | 463 knees | 245:218 | USA | 63 | 24 | WOMAC Pain | NA |
Arden et al57 | RCT | 474 knees | 185:289 | UK | 64 | 36 | WOMAC Pain | WOMAC Function |
Ayral et al58 | RCT | 665 knees | 259:406 | Australia, Belgium, Canada, Denmark, Finland, France, Hungary, Norway, Spain, UK, USA | 61.3 | 12 | WOMAC Pain | WOMAC Function |
Baselga Garcia-Escudero and Miguel Hernández Trillos59 | Observational cohort | 118 knees | 43:75 | Spain | 59.1 | 24 | NRS; WOMAC Pain | WOMAC Function |
Bevers et al60 | Observational cohort | 125 knees | 57:68 | The Netherlands | 57 | 24 | WOMAC Pain | WOMAC Function |
Bingham et al53 | RCT | 2483 knees | 735:1748 | USA Canada Austria Czech Republic France Germany Hungary Ireland Italy The Netherlands Poland Croatia | UTD | 24 | WOMAC Pain | WOMAC Function |
Birmingham et al61 | Observational cohort | 126 knees | 100:26 | Canada | 47.5 | 24 | KOOS Pain | KOOS Function; SF-36 Physical; LEFS |
Bisicchia et al52 | RCT | 150 knees | 47:103 | Italy | UTD | 12 | VAS Pain; SF-36 | SF-36 |
Brandt et al62 | RCT | 431 knees | 0:431 | USA | 54.9 | 30 | WOMAC Pain; VAS Pain | WOMAC Function |
Brown et al51 | RCT | 690 knees | 270:420 | USA | UTD | 32 weeks | WOMAC Pain; NRS weekly pain | WOMAC Function; SF-36 Function |
Brown et al50 | RCT | 621 hips | 237:384 | USA | UTD | 32 weeks | WOMAC Pain | WOMAC Function |
Bruyere et al63 | RCT | 319 knee | 0:319 | Belgium | 64.0 | 36 | WOMAC Pain | WOMAC Function |
Campbell et al49 | RCT | 100 knees | 28:72 | Australia | UTD | 120 | American Knee Society Score; WOMAC Pain | American Knee Society Score (function); WOMAC Function |
Chandrasekaran et al48 | Case control | 111 hips | 66:45 | USA | UTD | 24 | Modified Harris Hip Score; Nonarthritic hip score; VAS Pin | Modified Harris Hip Score; Nonarthritic hip score; Hip Outcome Score; Sports & ADLs |
Chandrasekaran et al47 | Case control | 186 hips | 96:90 | USA | UTD | 24 | Modified Harris Hip Score; Nonarthritic hip score; VAS Pin | Modified Harris Hip Score; Nonarthritic hip score; Hip Outcome Score; Sports & ADLs |
Conrozier et al 64 | RCT | 205 knees | 88:117 | France | 65 | 26 | WOMAC Pain; NRS walking pain | WOMAC Function |
Davis et al19 | Case control | 3132 knees | UTD | USA | UTD | 48 | WOMAC Pain; KOOS Pain | WOMAC Function |
Dougados et al46 | RCT | 507 hips | 202:305 | France | UTD | 36 | VAS Pain | Lequesne Index |
Dowsey et al65 | Observational cohort | 478 knees | 147:331 | Australia | 70.8 | 24 | IKSS Pain | IKSS Function |
Eckstein et al45 | RCT | 1412 knees | 611:801 | Austria | UTD | 48 | WOMAC Pain | NA |
Ettinger et al44 | RCT | 439 knees | 131:308 | USA | UTD | 18 | Pain intensity score | Physical Test |
Felson et al66 | Observational cohort | 3498 knees | 867:1206 | USA | 61.2 | 30 | WOMAC Pain | PASE |
Felson et al67 | Observational cohort | 330 knees | 111:2111 | USA | 62.1 | 15 | NA | Quadriceps strength (N) |
Filardo et al43 | RCT | 183 knees | 112:71 | Italy | UTD | 48 | KOOS Pain; IKDC | KOOS Function; Tegner; IKDC |
Glass et al42 | Observational cohort | 4648 knees | 918:1486 | USA | UTD | 24 | WOMAC Pain; NRS Pain | WOMAC Function |
Guermazi et al41 | Case control | 493 knees | 185:308 | USA | UTD | 60 | WOMAC Pain | PASE |
Hamilton et al68 | Observational cohort | 805 knees | 416:289 | UK | 66 | 30 | WOMAC Pain | WOMAC Function |
Hellio le Graverand et al69 | RCT | 1457 knees | 343:1114 | USA Canada Australia, Belgium, Czech Republic, Germany, Hungary, Italy, Poland, Russian Federation, Slovakia, Spain, Argentina Peru | 61.0 | 180 | Oxford Knee Score | Oxford Knee Score; American Knee Society Score; Tegner |
Henriksen et al40 | RCT | 157 knees | 28:129 | Denmark | UTD | 24 | WOMAC Pain | WOMAC Function |
Hill et al5 | RCT | 202 knees | 102:100 | Australia | 61 | 12 | KOO Pain | KOOS Function and kinematic assessment |
Hochberg et al70 | RCT | 522 knees | 84:438 | France Germany Poland Spain | 62.7 | 24 | WOMAC Pain | WOMAC Function |
Hoeksma et al71 | RCT | 109 hips | 33:76 | The Netherlands | 72 | 6 | WOMAC Pain; Huskisson’s VAS; EQ-5D Pain | WOMAC Function; EQ-5D Function |
Housman et al 39 | RCT | 391 knees | 130:261 | USA Canada France UK Germany | UTD | 6 | SF-36 Body Pain; Harris Hip Score; VAS Pain | SF-36 Function; Harris Hip Score; ROM |
Huang et al72 | RCT | 264 knees | 39:93 | Taiwan | 62 | 6 | WOMAC Pain | NA |
Huizinga et al73 | Observational cohort | 298 knees | 201:97 | The Netherlands | 51 | 12 | VAS Pain | Lequesne index; walking speed |
Jin et al6 | RCT | 413 knees | 205:208 | Australia | 63.2 | 24 | WOMAC Pain; VAS Pain | WOMAC Function |
Kahn et al74 | Observational cohort | 174 knees | 70:102 | USA | 67.0 | 6 | WOMAC Pain | WOMAC Function |
Karsdal et al38 | RCT | 2207 knees | 773:1424 | Denmark | UTD | 24 | WOMAC Pain | WOMAC Function |
Katz et al37 | RCT | 330 knees | 143:187 | USA | UTD | 12 | KOO Pain | WOMAC Function; SF-36 Function |
Kim et al75 | RCT | 352 knees | 9:153 | Republic of Korea | 68.1 | 144 | WOMAC | Knee Society Knee Score Function; ROM; UCLA Activity |
Kinds et al18 | RCT | 565 knees | UTD | The Netherlands | UTD | 60 | WOMAC Pain | WOMAC Function |
Kongtharvonskul et al 36 | RCT | 148 knees | 25:123 | Thailand | UTD | 6 | WOMAC Pain; VAS Pain | WOMAC Function |
Lequesne et al76 | RCT | 163 hips | 102:61 | France | 63.2 | 24 | VAS Pain | Lequesne Index |
Lohmander et al35 | RCT | 170 knees | 52:116 | Bulgaria Canada Croatia Finland Germany Poland Serbia Africa Sweden USA | UTD | 12 | WOMAC Pain | WOMAC Function |
Maheu et al8 | RCT | 345 hips | 159:186 | France | 62.2 | 36 | WOMAC Pain; Global Hip Pain | Lequesne Index; WOMAC Function; Global handicap NRS |
Marsh et al34 | RCT | 168 knees | 57:112 | Canada | UTD | 24 | WOMAC | WOMAC |
McAlindion et al33 | RCT | 146 knees | 57:89 | USA | UTD | 24 | WOMAC Pain | WOMAC Function; Physical Test |
Messier et al32 | RCT | 316 knees | 89:227 | USA | UTD | 18 | WOMAC Pain | WOMAC Function; Physical Test |
Messier et al77 | RCT | 142 knees | 37:105 | USA | 68.5 | 18 | WOMAC Pain | WOMAC Function; Physical Test |
Messier et al78 | RCT | 454 knees | 128:325 | USA | 66 | 18 | WOMAC Pain | WOMAC Function; Physical Test; SF-36 Physical |
Michel et al31 | RCT | 300 knees | 146:154 | Switzerland | UTD | 24 | WOMAC Pain | WOMAC Function; Physical Test |
Muraki et al79 | Observational cohort | 1558 knees | 553:1005 | Japan | 67.0 | 40 | WOMAC Pain | WOMAC Function; |
Muraki et al80 | Observational cohort | 1525 knees | 546:979 | Japan | 67.0 | 40 | WOMAC Pain | WOMAC Function |
Pavelka et al30 | RCT | 277 knees; 117 hips | 109:285 | Czech Republic | 58 | 60 | NA | Lequesne Index |
Pavelka et al81 | RCT | 202 knees | 45:157 | Czech Republic | UTD | 36 | WOMAC Pain | WOMAC Function; Lequesne Index |
Pham et al29 | Observational cohort | 301 knees | 97:204 | France | UTD | 12 | VAS Pain | Lequesne Index |
Podsiadlo et al28 | Observational cohort | 114 knees | 49:65 | Australia | UTD | 72 | WOMAC Pain | WOMAC Function |
Rat et al82 | RCT | 300 knees | 118:182 | France | 67 | 6 | SF-36 Body Pain; OAKHQOL Pain; VAS Pain | Lequense Index; SF-36 Physical; OAKHQOL Physical Activity |
Raynauld et al27 | RCT | 123 knees | 44:79 | Canada | UTD | 24 | WOMAC Pain | WOMAC Function |
Reginster et al26 | RCT | 212 knees | 50:162 | Belgium | UTD | 36 | WOMAC Pain | WOMAC Function |
Reginster et al83 | RCT | 1371 knees | 425:946 | Australia Austria Belgium Canada Czech Republic Denmark Estonia France Germany Italy Lithuania The Netherlands Poland Portugal Romania Russian Federation Spain UK | 62.9 | 36 | WOMAC Pain; VAS Pain | WOMAC Function |
Riddle and Jiranek25 | Observational cohort | 467 knees | 209:258 | USA | UTD | 24 | KOOS Pain | WOMAC Function |
Romagnoli et al84 | Observational cohort | 105 knees | 16:69 | Italy | 67.7 | 66 | Knee Society Score Clinical; VAS Pain | Knee Society Score Function; ROM |
Roman-Blas et al24 | RCT | 158 knees | 26:132 | Spain | UTD | 6 | WOMAC Pain; VAS Pain | WOMAC Function |
Rozendaal et al31 | RCT | 222 hips | 68:154 | The Netherlands | UTD | 24 | WOMAC Pain; VAS Pain | WOMAC Function |
Sanchez-Ramirez et al85 | Observational cohort | 186 knees | 59:127 | Canada | 61 | 24 | WOAMC Pain | WOMAC Function; Physical Test |
Sawitzke et al86 | RCT | 662 knees | 215:447 | USA | 57 | 24 | WOMAC Pain | WOMAC Function |
Skou et al87 | Observational cohort | 1682 knees | 434:818 | Denmark | 62.2 | 84 | WOMAC Pain | PASE; Physical Test |
Sowers et al88 | Observational cohort | 724 knees | 0:363 | USA | 56 | 132 | NA | WOMAC Function; Physical Test |
Spector et al89 | RCT | 284 knees | 115:169 | UK | 63.3 | 12 | WOMAC Pain | WOMAC Function |
Sun et al90 | RCT | 121 knees | 31:90 | Taiwan | 63 | 6 | WOMAC Pain; VAS Pain | WOMAC Function; Lequesne Index; Physical Test |
Urish et al22 | RCT | 336 knees | 96:67 | USA | UTD | 36 | WOMAC | WOMAC |
Valdes et al17 | Observational cohort | 860 knees; 928 hips | UTD | UK | UTD | 38 | WOMAC Pain | NA |
Van der Esch et al98 | Observational cohort | 402 knees | 64:137 | The Netherlands | 61.2 | 24 | NRS Pain | WOMAC Function; Physical Test |
Weng et al91 | RCT | 264 knees | 26:106 | Taiwan | 64 | 12 | VAS Pain | Lequesne Index; ROM; Physical Test |
White et al92 | Observational cohort | 2110 knees | 992:118 | USA | 61.0 | 84 | VAS Pain | WOMAC Function |
Witt et al93 | RCT | 294 knees | 70:154 | Germany | 64.0 | 12 | WOMAC Pain; SF-36 Body Pain; VAS Pain | WOMAC Function; SF-36 Function |
Yu et al21 | Observational cohort | 204 knees | 74:130 | Australia | UTD | 12 | KOOS Pain; VAS Pain | KOOS ADL; Physical Function |
Yusuf et al94 | Observational cohort | 74 knees; 31 hips; 11 hip and knees | 19:98 | The Netherlands | 60 | 72 | WOMAC Pain; SF-36 Body Pain; Pain on movement | WOMAC Function; SF-36 Function; Physical Test |
ADLs, activities of daily living; IKDC, International Knee Documentation Committee; KOOS, Knee Injury and Osteoarthritis Outcome Score; LEFS, Lower Extremity Functional Scale; NA, not applicable; NRS, Numerical Rating Scale; OAKHQOL, Osteoarthritis Knee and Hip quality of Life Questionnaire; PASE, Physical Activity Scale for the Elderly; RCT, randomised controlled trial; ROM, range of motion; SF-36, Short Form-36; UTD, unable to determine; VAS, Visual Analogue Scale; WOMAC, Western Ontario and Mcmaster Universities Osteoarthritis Index.